Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3532080 | 1.00 | HTT (0.55) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| SCHEMBL3532081 | 1.00 | HTT (0.55) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| SCHEMBL24106055 | 0.95 | EPHX1 (0.51) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| SCHEMBL1600934 | 0.89 | PDPK1 (0.59) | HTTALDH1A1SMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL2461645 | 0.89 | PDPK1 (0.59) | HTTALDH1A1SMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL598847 | 0.89 | PDPK1 (0.59) | HTTALDH1A1SMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL8613632 | 0.83 | HTT (0.56) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| Pyridine SCHEMBL28149473 | 0.80 | PDPK1 (0.49) | HTTALDH1A1TSHR | |
| SCHEMBL2115700 | 0.80 | HTT (0.63) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| SCHEMBL19120324 | 0.79 | ALDH1A1 (0.54) | HTTALDH1A1KMT2AMEN1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542961-B1 | TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE FOR USE IN TREATMENT OF CNS DISORDERS | SEPRACOR INC (US) | 2013-09-11 | — | — | EP | disclosed |
| US-8344030-B2 | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine | SUNOVION PHARMACEUTICALS INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2455075-A1 | Combinations of Eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, & Cognitive Disorders | Sepracor Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2012054110-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20070282007-A1 | TREATMENT OF PAIN DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE | SEPRACOR INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282007-A1 | TREATMENT OF PAIN DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE | HTR4, HTR1D, HTR1A | HTT 94/4885ALDH1A1 494/4885KMT2A 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.